Shanghai Yizhong Pharmaceutical Co Ltd

Shanghai Yizhong announced that its wholly-owned subsidiary Shanghai Youxichuang recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. The company's self-developed innovative drug YXC-001 has been officially approved for clinical trials in the treatment of advanced solid tumors. YXC-001 is a first-in-class trifunctional antibody fusion protein with a unique structure. By precisely integrating a PD-1 antibody, an anti-VEGF antibody, and optimized low-toxicity IL-2, it exerts synergistic effects in relieving immunosuppression, improving vascular barrier function and T cell infiltration, and targeted activation and expansion of effector cells in the tumor microenvironment.

Shanghai Yizhong announced that as of July 31, 2026, the company had repurchased a total of 780,000 shares, accounting for 0.38% of total share capital, with a repurchase amount of 29.8 million yuan, at a repurchase price range of 35.5 yuan to 40.39 yuan per share. In the first quarter of 2026, the company achieved revenue of 79.16 million yuan and net profit attributable to the parent of 18.17 million yuan.

The pharmaceutical sector rallied strongly during trading on the 6th, with weight-loss drug and innovative drug concepts standing out. Shouyao Holdings and Gan & Lee Pharmaceuticals were among multiple stocks that hit their daily limit up. As of press time, Shouyao Holdings surged by the 20 percent daily limit, Hotgen Biotech rose about 14 percent, Mabwell Bioscience, InventisBio, and Shanghai Yizhong Pharmaceutical gained over 10 percent, Gan & Lee Pharmaceuticals, Huahai Pharmaceutical, and Menovo Pharmaceutical also hit their daily limit up, BeiGene and Pharmaron climbed over 7 percent, and Hengrui Medicine advanced more than 5 percent. In the Hong Kong market, Duality Biologics, InnoCare Pharma, and Sino Biopharmaceutical rose over 10 percent, while WuXi XDC and Pharmaron gained more than 5 percent. On the news front, the National Medical Products Administration is soliciting public comments on optimizing the review and approval of cell and gene therapy drugs, encouraging clinically value-oriented R&D innovation, focusing on key areas such as malignant tumors and rare diseases, and placing eligible drugs into a 30-day review and approval pathway. Meanwhile, the overseas expansion of innovative drugs is accelerating. Since 2026, the total value of China's innovative drug license-out deals has reached 94.3 billion US dollars, up 81 percent year-on-year, with upfront payments reaching 5.5 billion US dollars, up 124 percent year-on-year, reflecting growing overseas recognition of China's innovative drug pipeline. CICC noted that leading innovative drug companies are shifting from the R&D investment phase into a positive cycle of commercial scale-up and overseas licensing revenue realization.